Dr Hamid
October 26, 2022
Interesting article that shows semaglutide effectively reduces body adiposity
STUDY OF EARLY RETINAL CHANGES IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS - PubMed
In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the ..... see more
Conclusions: In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the AVR index correlates with age and nighttime BP, highlighting the important contribution of the latter in early target organ damage in this...
The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study - PubMed
doi: 10.3390/medicines9090047. 1 Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan. 2 Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, ..... see more
Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre
Although national diabetes guidelines recommend targets for various health parameters, studies have demonstrated a gap between recommendations and real-life practice. The objectives of the present study were to: 1) assess ..... see more
Source : https://www.canadianjournalofdiabetes.com/article/S1499-2671(22)00211-8/fulltext
Conclusions: Patients with T2DM at the MUHC receive guideline-based measurements of health parameters more frequently than at other institutions. Achievement of target values was closer to that seen by Canadian specialists than by primary care. Although further analyses are necessary to help implement effective strategies for improvement,...
Show More Comments
-
Dr Hamid October 26, 2022
Interesting article, but further analyses are necessary to help implement effective strategies for improvement -
Amy Gonzales, Physician October 16, 2022
Screening and counseling are important in preventing diabetes.
Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF - PubMed
1 Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA. 2 Department of Physiology, Wayne State University, Detroit, MI 48202, USA. ..... see more
Conclusions: AMP-activated protein kinase (AMPK) pathways in ALDH2*2 mice with diabetes-associated HFpEF. This combination was even more effective than EMP alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes-associated HFpEF.
The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy
Objective: To explore the significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy (DN) and its effects on renal function indices. Methods: Three hundred ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452308/
Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study - BMC Endocrine Disorders
Background IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin therapy. However, the evaluation of its real-world effectiveness ..... see more
Source : https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-01139-8
Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan
Excess glucose excretion and diuresis with sodium-glucose co-transporter 2 inhibitors may cause dehydration during Ramadan. * Clinical and biochemical markers of dehydration existed with sodium-glucose co-transporter 2 inhibitors during Ramadan. ..... see more
Source : https://www.sciencedirect.com/science/article/abs/pii/S187140212200220X?via=ihub
Show More Comments
-
Dr Hamid September 12, 2022
Important study to detect the potential alteration of hydration status in adult Muslims with type 2 diabetes mellitus (T2D) who used SGLT2i during Ramadan.
Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus - PubMed
Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the ..... see more
Conclusions: Conclusion/Relevance: Sodium-glucose cotransporter 2 inhibitor of empagliflozin is a potent anti-hyperglycemic agent. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In current study, we review the available clinical data on the potential renoprotective...
Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials - PubMed
Only a few meta-analyses evaluated the effect of finerenone on cardiovascular events in type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). The main aim of this meta-analysis was ..... see more
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice
Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/
Conclusion/Relevance: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.
Show More Comments
-
Dr Hamid August 23, 2022
Patients with T2D and CKD who develop macroalbuminuria have a greater risk of cardiovascular disease mortality than progression to ESKD
Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors
Type 2 diabetes mellitus (T2DM) is a set of metabolic disorders specified by hyperglycemia as a result of abnormalities in insulin secretion or sensitivity. Chronic kidney disease (CKD) and cardiovascular ..... see more
Relevance: Combinations such as empagliflozin and linagliptin, ertugliflozin and metolazone, dapagliflozin and sacubitril-valsartan and many more show promising results. Here, we have reviewed the ongoing and completed clinical trials, addressed current theories, and discussed necessary future research to explain the possible risks and...
Show More Comments
-
Dr Hamid August 23, 2022
Chronic kidney disease (CKD) and cardiovascular disease (CVD) are the widespread co-morbidities of T2DM and share risk factors for onset and progression
Glucose-Lowering Treatment Patterns in Patients With Diabetic Kidney Disease
Objectives: Recent trials of glucose-lowering drugs (GLDs) have drawn attention to renal outcomes. Our goal was to understand how patients with diabetic kidney disease (DKD) are treated in general practices ..... see more
Conclusions: Real-world treatment of DKD in the United States is suboptimal. Inappropriate use of some GLD classes, especially in advanced DKD stages, was found along with lower than expected use of modern agents that are considered safe and effective to treat glycemic outcomes. Efforts may be needed to improve understanding of safety,...
Diabetes and Impaired Fracture Healing: A Narrative Review of Recent Literature - Current Osteoporosis Reports
Purpose of the Review Diabetes mellitus is a chronic metabolic disorder commonly encountered in orthopedic patients. Both type 1 and type 2 diabetes mellitus increase fracture risk and impair fracture ..... see more
Source : https://link.springer.com/article/10.1007/s11914-022-00740-z
Practical Considerations for Use of Insulin/Glucagon-Like Peptide 1 Receptor Agonist Combinations in Older Adults With Type 2 Diabetes - PubMed
Over 25% of adults ≥65 years of age have type 2 diabetes (T2D). Individualization of care is important in older adults with T2D, with treatment targets and therapeutic approaches informed ..... see more
Conclusion/Relevance: Fixed-ratio combination injectable products offer unique benefits in older adults, including reduction of both fasting and postprandial glucose, low hypoglycemia risk, lack of weight gain, fewer gastrointestinal side effects, strong durability of effect, and the potential for medication regimen simplification.
Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials - PubMed
Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of ..... see more
Conclusions: Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of biosimilar insulins compared with that of reference insulins, healthcare professionals and insulin users must gain further awareness and...
Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
AimsThis study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another ..... see more
Source : https://www.frontiersin.org/articles/10.3389/fendo.2022.892702/full
A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have gained an important place in the management of diabetes management because of their exceptional glucose-lowering, weight lowering and cardiovascular (CV) benefits. Despite recommendations ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302409/
A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis - PubMed
Evidence is strongest for liraglutide compared to other licensed WLMs. The findings, particularly the inclusion of human trial data, provide evidence for liraglutide use in treating AIWG and OSP, which ..... see more
Conclusion: Evidence is strongest for liraglutide compared to other licensed WLMs. The findings, particularly the inclusion of human trial data, provide evidence for liraglutide use in treating AIWG and OSP, which would better align psychiatric practice with non-psychiatric practices around obesity. The findings also identify continued...
Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study - Diabetology & Metabolic Syndrome
Background After initiating cardioprotective agents, a fall of estimated glomerular filtration rate (eGFR) has been reported in several studies. Our goal was to evaluate the accuracy of change of Chronic ..... see more
Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00874-1
Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study - PubMed
1 Division of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan. 2 Core Research Facilities for Basic Science, Research Center for Medical Sciences The Jikei University School of Medicine Tokyo ..... see more
Show More Comments
This reminds of what I learned in med school. Patients with type 1 DM should see their eye doctor every ~5 yrs for screening. For patient with type 2 DM, Show More